Merck recently announced that it will pay $688 million to settle two class action lawsuits brought by pension funds and other shareholders. The investors accused the company of withholding n... Read more
Merck has settled a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin. U.S. District Judge Thoma... Read more
Merck & Co. has settled a patent dispute with Glenmark Pharmaceuticals involving the cholesterol drug Zetia, one of its best-selling products. The lawsuit had been scheduled to go to tri... Read more
The Food and Drug Administration says that the highest available dose of the cholesterol drug Zocor can cause muscle damage as well as severe and potentially lethal kidney damage. The agency... Read more
The Food and Drug Administration says patients should not stop taking Vytorin or other cholesterol-lowering drugs, based on its review of a controversial study. The agency is sticking to its... Read more
There have several lawsuits filed against Merck & Co. and partner Schering-Plough Corp., related to their marketing of cholesterol drug Vytorin. Also, the U.S. Department of Justice is i... Read more
U.S. drug regulators are investigating whether the cholesterol-lowering drug Vytorin might be linked to cancer. The U.S. Food and Drug Administration informed health-care professionals that... Read more
Information revealed last month to a Congressional committee relating to drug trials is very disturbing. The lead outside investigator on a crucial trial of two widely used heart drugs said... Read more
The Department of Justice has joined federal lawmakers in seeking information about why it took drug makers so long to report the negative results of a study of the cholesterol drug Vytorin.... Read more
Dr. Steve Nissen, a noted cardiologist, wants the Food and Drug Administration to raise its standards for approving diabetes drugs. Dr. Nissen, who is with the Cleveland Clinic, says that ne... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.